DALLAS and FORT WORTH, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a
pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its
proprietary modified-release drug delivery technologies, today announced that Vipin K. Garg, Ph.D., President and CEO of Neos
Therapeutics, will present a company overview at the upcoming UBS Global Healthcare Conference on Tuesday, May 22, 2018 at 9:30
a.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at
http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products
utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT®
(methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine)
extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the
first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets
its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and
chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is
available at www.neostx.com.
1Tussionex® is a registered trademark of the UCB Group of Companies.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
